Chai, an AI drug-discovery platform, has partnered with Bristol Myers Squibb to apply artificial intelligence to antibody discovery for potential disease treatments.
The collaboration signals pharmaceutical companies' increasing reliance on AI to accelerate research and potentially reduce development costs, though specific details about the scope and timeline have not been disclosed.
What happened
Chai, an AI platform for drug discovery, announced a collaboration with Bristol Myers Squibb to use AI for identifying antibodies that could treat disease.
Why it matters
AI-driven antibody discovery could accelerate the timeline and reduce costs for developing new therapeutic candidates, an area where traditional methods are slow and expensive. For pharmaceutical companies, this represents a pathway to speed up their research pipelines.
What to watch
The specific scope, timeline, and financial terms of the partnership were not detailed in the announcement.
Ask the AI about this article →
The collaboration reflects a broader trend in the pharmaceutical industry toward integrating artificial intelligence into early-stage research. Antibody discovery is a capital- and time-intensive process in traditional drug development, making it a natural candidate for AI acceleration. By partnering with Chai, Bristol Myers Squibb is leveraging a specialized AI capability rather than building the infrastructure internally, a model that several major pharma companies have adopted in recent years.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Hark and AT&T have announced a partnership focused on providing connectivity solutions for future AI devices
John Deere raised its full-year 2026 profit guidance after reporting a quarterly earnings beat driven by stron…
AT&T is deploying open-source AI models to reduce its reliance on Anthropic's commercial services and lower it…
Zayo, a network infrastructure provider, has expanded its partnership with Corning, a materials science compan…
The pharmaceutical industry is increasing investment in artificial intelligence to accelerate drug discovery a…
Gemini AI added 514 shares of NextEra Energy (NYSE: NEE) to its AI-run portfolio on Rallies, purchasing betwee…
